Cytochrome P450 2A6 (CYP2A6) Genotyping
CYP2A6 is an enzyme predominantly expressed in the liver, in the lung, trachea, nasal mucosa, and sex organs such as breast, responsible for the clearance of many drugs and environmental chemicals. It is also responsible for the oxidation of nicotine and cotinine (COT). To date, 35 different CYP2A6 alleles have been described. Alleles conferring increased enzyme activity (rapid metabolizers) result in enhanced rates of nicotine metabolism and are associated with increased cigarette consumption. Individuals with allelic variants with decreased activity (slow metabolizer phenotype) do not efficiently metabolize coumarin or nicotine. For example, slow metabolizers (as determined by CYP2A6 *2, *4, *9 and *12 alleles), are less likely to be smokers, have lower levels of dependence and are more able to quit and benefit more from regular and extended nicotine patch replacement therapy compared to normal metabolizers.
CYP2A6 alleles also are associated with activation of carcinogens from tobacco and xenobiotics. For instance, in tobacco users CYP2A6 polymorphisms possessing lower enzyme activity are associated with reduced risk of lung, oral, head and neck, and upper aerodigestive cancers. CYP2A6 is also involved in the metabolisms of several cancer therapeutics such as Tegafur and Letrozle, as well as antibiotics for infectious diseases including Efavirenz, Artemisinin and derivatives.
- Evaluation of tobacco smoking behavior and nicotine dependence
- Determine therapeutic strategy for drugs metabolized by CYP2A6 enzyme (cancer therapeutics such as Tegafur and Letrozle, and infectious diseases drugs such as Efavirenz, Artemisinin and derivatives)
Slow metabolizers (as determined by CYP2A6 *2, *4, *9 and *12 alleles), are less likely to be smokers, have lower levels of dependence, are more able to quit, and benefit more from regular and extended nicotine patch replacement therapy then normal metabolizers.
Based on genetic variation and enzyme activity several CYP2A6 phenotypes have been described:
“Poor metabolizer” indicates no active CYP2A6 enzyme;
“Slow metabolizer” indicates one inactive or two decreased activity alleles
“Intermediate metabolizer” is heterozygous with one decreased activity allele and one active allele
“Normal”/”Extensive” carries 2 active alleles, while “Ultrarapid”/”Fast” may contain 2 hyperactive alleles.
Caffeine *1/*4, *4/*9 or *1/*9 display significantly reduced 8-hydroxylase enzyme activity against paraxanthine, and 4/4 samples have undetectable activity
Tegafur
Tegafur is a pro-drug. It is metabolized into 5’ hydroxytegafur, which breaks down into 5-fluorouracil (5FU) and is further processed into active metabolites. CYP1A2, CYP2C8, CYP2C9, CYP1A1 and CYP2A6 have a principle role in the biotransformation of tegafur into 5FU. In vivo study showed the *4C and *11 alleles conferred poor tegafur metabolism, whereas a *1B is associated with elevated rates of 5 FU formation. S-1 and cisplatin-treated patients with two CYP2A6 variant alleles *4, *7, *9, *10, or the *1/*4 genotype, have significantly lower treatment response rates, increased risk of disease progression and increased likelihood of reduced overall survival time than other genotypes.
Letrozole
CYP2A6 has a major role in the breakdown of letrozole into its inactive carbinol metabolite. In vitro study showed CYP2A6 genotypes *1/*4, *4/*4, *4/*9 and *1/*7 had significantly reduced letrozole oxidation.
Efavirenz
Efavirenz (EFV) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that suppresses viral replication and is used as a component in highly active anti-retroviral therapy regimens for HIV-infected patients. CYP2B6 has a key role in efavirenz metabolism, predominantly forming the major metabolite 8-hydroxyefavirenz. *1/*4 or *4/*4 or *4/*9 or *1/*7 significantly associate with lower response rate.
CYP2A6 \*1 is normal metabolizer
Whole blood collected in lavender top tube (EDTA) or any anticoagulant collection devices. Buccal swab is also used.
Stability
- Ambient: 5 days
- Refrigerated: 7 days
- Br J Cancer. 2011 Mar 29;104(7):1126-34. [PMID: 21364592]
- N Engl J Med. 2003 Jun 12;348(24):2431-42. [PMID: 12802030]
- Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):95-103. [PMID: 20001610]
- Pharmacogenet Genomics. 2005 Sep;15(9):609-24. [PMID: 16041240]
- Drug Metab Dispos. 2001 Feb;29(2):91-5. [PMID: 11159795]
- Adv Drug Deliv Rev. 2002 Nov 18;54(10):1245-56. [PMID: 12406643]
- Pharmacogenomics. 2007 Oct;8(10):1385-402. [PMID: 17979512]
- Pharmacogenomics. 2011 Apr;12(4):481-92. [PMID: 21521021]